|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-5-30
|
|
pubmed:abstractText |
The integrin alpha v beta3 receptor is upregulated on tumor cells and endothelium and plays important roles in angiogenesis and metastasis. Arg-Gly-Asp (RGD) peptide ligands have high affinity for these integrins and can be radiolabeled for PET imaging of angiogenesis or tumor development. We have assessed the safety, stability, and tumor distribution kinetics of a novel radiolabeled RGD-based integrin peptide-polymer conjugate, 18F-AH111585, and its feasibility to detect tumors in metastatic breast cancer patients using PET.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0161-5505
|
|
pubmed:author |
pubmed-author:AboagyeEric OEO,
pubmed-author:Al-NahhasAdilA,
pubmed-author:CohenPamela SPS,
pubmed-author:ContractorKaiyumars BKB,
pubmed-author:CoombesR CharlesRC,
pubmed-author:GlaserMatthiasM,
pubmed-author:HuiAi-MinAM,
pubmed-author:KennyLaura MLM,
pubmed-author:McParlandBrianB,
pubmed-author:MillerMatthewM,
pubmed-author:OsmanSafiyeS,
pubmed-author:OulieIngerI,
pubmed-author:PalmieriCarloC,
pubmed-author:SpinksTerence JTJ,
pubmed-author:TurtonDavidD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
879-86
|
|
pubmed:meshHeading |
pubmed-meshheading:18483090-Adult,
pubmed-meshheading:18483090-Aged,
pubmed-meshheading:18483090-Breast Neoplasms,
pubmed-meshheading:18483090-Female,
pubmed-meshheading:18483090-Humans,
pubmed-meshheading:18483090-Metabolic Clearance Rate,
pubmed-meshheading:18483090-Middle Aged,
pubmed-meshheading:18483090-Oligopeptides,
pubmed-meshheading:18483090-Organ Specificity,
pubmed-meshheading:18483090-Peptides,
pubmed-meshheading:18483090-Polyethylene Glycols,
pubmed-meshheading:18483090-Positron-Emission Tomography,
pubmed-meshheading:18483090-Radiopharmaceuticals,
pubmed-meshheading:18483090-Tissue Distribution
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
|
|
pubmed:affiliation |
Department of Oncology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
